WHA77 individual statement on the Working Group on Amendments to the International Health Regulations (2005)
On 28 May 2024, IFPMA submitted a statement at the World Health Assembly on Provisional Agenda Item 13.3, Working Group on Amendments to the International Health Regulations (2005).
IFPMA acknowledges and appreciates the substantial efforts made by Member States in advancing the text of the Working Group on Amendments to the International Health Regulations (WGIHR). We recognize the dedication and collaboration that have brought us to this stage, reflecting a shared commitment.
The pharmaceutical industry is committed to the principle of equity in global health. However, while progress has been made, the current draft still has open issues that may present challenges and have a counterproductive impact
The lack of clarity on many key definitions and the ongoing discussions at the Intergovernmental Negotiating Body (INB), which are cross-referenced in the document, complicate our ability to fully assess and provide comprehensive feedback on the proposed amendments. In addition, we urge Member States to ensure that technology transfer remains voluntary and on mutually agreed terms.
We remain committed to working with Member States and stakeholders to achieve a robust and successful outcome.
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
